Billionaire Seth Klarman’s Favorite Healthcare Stocks

BAUPOST GROUPThe Baupost Group, managed by value investor Seth Klarman (author of Margin of Safety), is one of the largest hedge funds in the world. It invests in a range of industries, but in the fund’s 13F filing for the second quarter of 2012 we noticed a number of healthcare companies in prime positions in its portfolio (see other stocks the Baupost Group owns). It can be difficult to evaluate some healthcare companies, so investors may want to take the fund’s investment as a seal of approval and give that some consideration as they buy stocks themselves. Here are the Baupost Group’s three largest healthcare positions as of the end of June:

Theravance Inc (NASDAQ:THRX) was Bauposts’s top healthcare holding, with the fund disclosing a position of 14.6 million shares. This was unchanged from the previous quarter. Theravance researches and develops medications, with its primary products treating bacterial infections and chronic obstructive pulmonary disease. At the moment its drugs are still in development mode and the company is expected to take net losses for both this year and next year. So far in 2012 the stock is up 31% bringing the company’s market capitalization to $2.6 billion. Iridian Asset Management also had a position in the stock as of the end of June.

Klarman and his team increased Baupost’s stake in Idenix Pharmaceuticals Inc (NASDAQ:IDIX) to 10 million shares, placing it just a bit behind Bain Capital’s Brookside Capital in our database of major hedge fund positions. Idenix’s primary product is an attempt to treat the hepatitis C virus, and has an agreement to work with Novartis to develop and produce drugs. As their product is still in development, they have the same situation as Theravance: Idenix is not expected to turn a profit in 2012 or 2013. It should also be noted that Baupost and Brookside combined own about 16% of the company’s shares outstanding.

AVEO Pharmaceuticals (NASDAQ:AVEO), fitting the pattern, is another top Baupost pick in the healthcare sector which is not expected to turn a profit any time soon. It’s also another stock that the fund owns a large piece of: its 5.1 million shares from the end of the second quarter, unchanged since the end of March, mean that it owns about 12% of AVEO’s shares outstanding. AVEO is researching a variety of cancer drugs, including an oral cancer drug that limits tumor growth and is currently in Phase III clinical trials. The stock is down 31% this year, with much of that loss coming in early August after the company reported that the previously mentioned drug will require additional data analysis before an FDA decision. Baupost is mostly on its own on this one with respect to the hedge fund community: no other fund tracked by Insider Monkey had a position worth over $5 million.

All three of these cases are speculative pharmaceutical companies. They are currently unprofitable and therefore depend on seeing their drugs in development become successful and marketable at a reasonable price. It is difficult for many investors to evaluate the likelihood that these products will end up succeeding, so it might be helpful to start by limiting the universe of emerging pharmaceutical stocks to those where fund managers with a track record of success have committed capital to the company. Klarman’s track record is good enough that we think Baupost is such a fund whose activities in the pharmaceutical industry should be watched. Of course, it’s also interesting to note that despite its value background Baupost prefers these stocks to more established healthcare companies including major drug manufacturers and direct care providers.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!